BioPharma Dive2h
FDA clears use of Ozempic to protect kidney health
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)
TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...
BMO maintains Novo Nordisk stock target post FDA nod
BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
F.D.A. Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...
Novo Nordisk's Ozempic gets FDA approval for kidney disease
Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...